Compare Natco Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PIRAMAL ENTERPRISES NATCO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 15.5 16.8 92.4% View Chart
P/BV x 3.0 1.1 273.0% View Chart
Dividend Yield % 1.1 1.6 69.7%  

Financials

 NATCO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
NATCO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8493,303 25.7%   
Low Rs5571,797 31.0%   
Sales per share (Unadj.) Rs573.8716.5 80.1%  
Earnings per share (Unadj.) Rs176.079.7 220.8%  
Cash flow per share (Unadj.) Rs198.2107.9 183.7%  
Dividends per share (Unadj.) Rs6.2528.00 22.3%  
Dividend yield (eoy) %0.91.1 81.0%  
Book value per share (Unadj.) Rs842.71,477.5 57.0%  
Shares outstanding (eoy) m36.50184.45 19.8%   
Bonus/Rights/Conversions BBIS-  
Price / Sales ratio x1.23.6 34.4%   
Avg P/E ratio x4.032.0 12.5%  
P/CF ratio (eoy) x3.523.6 15.0%  
Price / Book Value ratio x0.81.7 48.3%  
Dividend payout %3.635.1 10.1%   
Avg Mkt Cap Rs m25,660470,292 5.5%   
No. of employees `0005.07.8 63.4%   
Total wages/salary Rs m3,55922,504 15.8%   
Avg. sales/employee Rs Th4,225.316,899.4 25.0%   
Avg. wages/employee Rs Th718.02,877.7 24.9%   
Avg. net profit/employee Rs Th1,295.91,879.9 68.9%   
INCOME DATA
Net Sales Rs m20,945132,153 15.8%  
Other income Rs m1,3023,128 41.6%   
Total revenues Rs m22,247135,281 16.4%   
Gross profit Rs m7,94866,290 12.0%  
Depreciation Rs m8105,202 15.6%   
Interest Rs m19344,097 0.4%   
Profit before tax Rs m8,24720,119 41.0%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8238,611 21.2%   
Profit after tax Rs m6,42414,701 43.7%  
Gross profit margin %37.950.2 75.7%  
Effective tax rate %22.142.8 51.6%   
Net profit margin %30.711.1 275.7%  
BALANCE SHEET DATA
Current assets Rs m23,472122,742 19.1%   
Current liabilities Rs m7,287310,810 2.3%   
Net working cap to sales %77.3-142.3 -54.3%  
Current ratio x3.20.4 815.6%  
Inventory Days Days9223 399.7%  
Debtors Days Days8839 227.1%  
Net fixed assets Rs m18,648116,904 16.0%   
Share capital Rs m365369 98.9%   
"Free" reserves Rs m34,525272,161 12.7%   
Net worth Rs m30,760272,530 11.3%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m43,031856,261 5.0%  
Interest coverage x43.71.5 3,003.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.50.2 315.4%   
Return on assets %15.46.9 223.9%  
Return on equity %20.95.4 387.2%  
Return on capital %27.412.4 220.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,53615,200 75.9%   
Fx outflow Rs m2,9394,889 60.1%   
Net fx Rs m8,59710,312 83.4%   
CASH FLOW
From Operations Rs m6,688-115,975 -5.8%  
From Investments Rs m-6,122-8,265 74.1%  
From Financial Activity Rs m-509107,525 -0.5%  
Net Cashflow Rs m66-16,650 -0.4%  

Share Holding

Indian Promoters % 52.0 52.9 98.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.0 196.0%  
FIIs % 16.6 26.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 16.5 157.6%  
Shareholders   25,395 93,274 27.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 15, 2019 03:37 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS